Evidence map›Paper›PMID 34625610›Full record

ArticleScientific reports2021

SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray.

Krzysztof Pyrć, Aleksandra Milewska, Emilia Barreto Duran, Paweł Botwina, Agnieszka Dabrowska, Malwina Jedrysik, Malgorzata Benedyk, Rui Lopes, Alejandro Arenas-Pinto, Moutaz Badr and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Krzysztof PyrćLaboratory of Virology and ABSL3 Animal Facility at the Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387, Krakow, Poland.ORCID 0000-0002-3867-7688
Aleksandra MilewskaLaboratory of Virology and ABSL3 Animal Facility at the Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387, Krakow, Poland.
Emilia Barreto DuranLaboratory of Virology and ABSL3 Animal Facility at the Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387, Krakow, Poland.ORCID 0000-0002-9152-5552
Paweł BotwinaLaboratory of Virology and ABSL3 Animal Facility at the Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387, Krakow, Poland.
Agnieszka DabrowskaMicrobiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland.
Malwina JedrysikLaboratory of Virology and ABSL3 Animal Facility at the Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, 30-387, Krakow, Poland.
Malgorzata BenedykMicrobiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland.
Rui LopesNanomerics Ltd., 6th Floor, 2 London Wall Place, London, EC2Y 5AU, UK.
Alejandro Arenas-PintoCentre for Clinical Research in Infection and Sexual Health, UCL Institute for Global Health, Mortimer Market Centre, off Capper Street, London, WC1E 6JB, UK.ORCID 0000-0002-3368-5005
Moutaz BadrNanomerics Ltd., 6th Floor, 2 London Wall Place, London, EC2Y 5AU, UK.ORCID 0000-0003-0737-1894
Ryan MellorNanomerics Ltd., 6th Floor, 2 London Wall Place, London, EC2Y 5AU, UK.
Tammy L KalberCentre for Advanced Biomedical Imaging (CABI), Division of Medicine, University College London, London, WC1E 6DD, UK.ORCID 0000-0002-3378-3748
Delmiro Fernandez-ReyesComputer Science Department, University College London, Gower Street, London, WC1E 6BT, UK.ORCID 0000-0001-5070-9198
Andreas G SchätzleinNanomerics Ltd., 6th Floor, 2 London Wall Place, London, EC2Y 5AU, UK.ORCID 0000-0003-3907-6603
Ijeoma F UchegbuNanomerics Ltd., 6th Floor, 2 London Wall Place, London, EC2Y 5AU, UK. ijeoma.uchegbu@ucl.ac.uk.
Jagiellonian University · PLUniversity College London · GBCAB International · GBMRC Clinical Trials Unit at UCL · GBUniversity of Suffolk · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are currently no cures for coronavirus infections, making the prevention of infections the only course open at the present time. The COVID-19 pandemic has been difficult to prevent, as the infection is spread by respiratory droplets and thus effective, scalable and safe preventive interventions are urgently needed. We hypothesise that preventing viral entry into mammalian nasal epithelial cells may be one way to limit the spread of COVID-19. Here we show that N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ), a positively charged polymer that has been through an extensive Good Laboratory Practice toxicology screen, is able to reduce the infectivity of SARS-COV-2 in A549

Indexed as

COVID-19 Drug TreatmentNasal SpraysA549 CellsAnimalsAntiviral AgentsChlorocebus aethiopsHumansMaleMethylationMiceMice, Inbred BALB CMice, TransgenicSARS-CoV-2Surface-Active AgentsVero CellsViral LoadAntiviral AgentsNasal SpraysSurface-Active Agents

Identifiers

PMID34625610
PMCPMC8501059
OpenAlexW3202286872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.